NeuCyte, Inc., an innovative b<₩iotech company focused on deve εloping novel treatmenλ•≥♠ts for neurological d☆≠∑isorders, today announced that☆♥π• it has entered into an ex ♠clusive license agreement with Trillium Therapeu¥∑tics to advance an undisclosed preclinical ←←₩compound with potential utility in treating>♣ refractory epilepsy in the form of Dβ★ravet syndrome and rela'¥βted disorders.The compound covered by this agree≈•±ment has demonstrated highly  ¶encouraging activity during studies conducσ®ted by the National Institute of N←ε$eurological Disorders and Stroke ≥α₩$(NINDS) Epilepsy Therapy Screening Program (ETSP)ε'. It demonstrates a superiorπ™ safety and anti-seizure efficacy pro ★file over NINDS benchm ‍₹ark anti-epileptic drugs ₽<™(AEDs) in eleven animal models. It‌‌¥¶ has also demonstrated broad efficacy i ​"n NIH animal studies for ®∞pharmaco-resistant epile'♠★ psy.  As a result, this novel agent has g≥≥ained the prestigious NIN•±DS Red Book status and been se♥‌lected as a promising lead drug candidate."Th>λ♦γis compound is an exceedingly promising<<♥ antiseizure drug which, although in preclini₽'β cal development, is quite e≠™✘fficacious in a wide variety of highlεδ•y predictive seizure ™φ¶models," said Roger J.€​≈£ Porter, MD, Adjunct Professor of Neurology at t‌₽he University of Pennsylva​↕↑εnia, former Deputy Di ©∞rector of NINDS, former Chairman o♥​f the White House Committee on Brain ∑ and Behavioral Sciences, and former ★•President of American Epilepsy Society. "It <'σ may prove very effective for patients with epi  lepsy." As a first-in-class compound withα '® unique mechanism of action prof<♠iles, this drug candidate is likely to hav←α¥e activity across a variety of indications. The f¥βδαavorable efficacy and safety pr↕÷ofile has also been validated by NeuCyte's prop↕  rietary in vitro human iPSC-d¥‌÷‌erived models."Epilepsy is the fourt♠®¶h most common neurological disease af♣± ¶fecting more than 65 million σ‍≤∏people of all ages worldwide. The$¥< complex and multifactorial nature of the ≈βdisorders makes treatment complicated and c→♣​‌hallenging. Up to 40% of ne±∏wly diagnosed epilepsy patients ∏®₩are resistant to current thera δpies which highlights the urg₩♠π ent need to develop first-in-class treatments,¶♠≥←" said Jacqueline A. French, MD, Chief Medi×π cal and Innovation Officer of ♣✔'the Epilepsy Foundation and epileptologiα®♣st in New York City. "It is very encouraging ★&δto see new developments and therap ε₩eutic candidates in this disease area."Under γ£≠'the terms of the agree♥↑&§ment, Trillium has granted N&λeuCyte exclusive, worldwide  ​& rights to develop and commercialize the <₽compound.  "NeuCyte is뮥± committed to bringing breakthrough ther£≥βapies to epilepsy patients and believ&∏≠e that our advantageous translational tec♣β©hnology platform and CNS expertise enable♣  us to optimally advance such thera≤₩∏™peutic candidates," said Tao Huang"φ¶, PhD, JD, President an‍∏≠✔d Chief Executive Officer of NeuCyte. "This l"β≈icensing agreement allows ≤≥ ‌us to expand our pipeline and≥♠ advance our goal of meeting unmet clinical σ÷¶<needs and truly improving patient care and  $ quality of life."informa₹Ω•tion source:pharma focus A ✔siaThe original link:https:https:ht≠<γφtps://www.pharmafocusasia.com/news/neucyte-lic☆ enses-promising-nove‌ ‌♣l-compound-for-treatment-of-refra$Ωctory-epilepsy-and-relσ÷ated-neurological-disorde §rs2019 Asia-pacific pharma IP Leader Sum☆"mit:http://en.zenseegro₽☆₽up.com/p/510934/will be held in Beijing$§α≠  on N∏✔ovember 14-15, and will at★βtract more than 500 industr¥λ×'y experts from domes↕←γ₹tic and foreign pharmaceutical companies, biot♣→echnology companies, governments, assoc₹≥↓₩iations, law firms, intellectual property agents £←ε and other companies to attend.Official<" registration and consultation channels:Con↓§tact：AnnPhone: 021-65650305Email：Marketing@♣φ₩♥zenseegroup.comhttp:₩$∏λ//en.zenseegroup.com/p/5109 ±α₹34/